Filter by Topic
- People (190) Apply People filter
- Reproduction (118) Apply Reproduction filter
- Publications (116) Apply Publications filter
- Experiments (103) Apply Experiments filter
- Processes (93) Apply Processes filter
- Theories (76) Apply Theories filter
- Technologies (71) Apply Technologies filter
- Disorders (64) Apply Disorders filter
- Legal (35) Apply Legal filter
- Ethics (30) Apply Ethics filter
- Organizations (25) Apply Organizations filter
- Organisms (17) Apply Organisms filter
- Outreach (12) Apply Outreach filter
- Religion (3) Apply Religion filter
- Places (2) Apply Places filter
- DNA (1) Apply DNA filter
- Publication (1) Apply Publication filter
- Reproductive Health Arizona (1) Apply Reproductive Health Arizona filter
"Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells" (2007), by Junying Yu et al.
On 2 December 2007, Science published a report on creating human induced pluripotent stem (iPS) cells from human somatic cells: "Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells." This report came from a team of Madison, Wisconsin scientists: Junying Yu, Maxim A. Vodyanik, Kim Smuga-Otto, Jessica Antosiewicz-Bourget, Jennifer L. Frane, Shulan Tian, Jeff Nie, Gudrun A. Jonsdottir, Victor Ruotti, Ron Stewart, Igor I. Slukvin, and James A. Thomson.
Human Embryonic Stem Cells
Stem cells are undifferentiated cells that are capable of dividing for long periods of time and can give rise to specialized cells under particular conditions. Embryonic stem cells are a particular type of stem cell derived from embryos. According to US National Institutes of Health (NIH), in humans, the term "embryo" applies to a fertilized egg from the beginning of division up to the end of the eighth week of gestation, when the embryo becomes a fetus. Between fertilization and the eighth week of gestation, the embryo undergoes multiple cell divisions.
Subject: Processes, Reproduction
Stem Cell Tourism
When James Thomson of the University of Wisconsin announced in 1998 that he had derived and cultured human embryonic stem cells(hESCs), Americans widely believed-and accepted-that stem cells would one day be the basis of a multitude of regenerative medical techniques. Researchers promised that they would soon be able to cure a variety of diseases and injuries such as cancer, diabetes, Parkinson's, spinal cord injuries, severe burns, and many others. But it wasn't until January 2009 that the Food and Drug Administration approved the first human clinical trials using hESCs.
Hematopoietic Stem Cell Transplantation
The purpose of regenerative medicine, especially tissue engineering, is to replace damaged tissue with new tissue that will allow the body to resume normal function. The uniqueness of tissue engineering is that it can restore normal structure in addition to repairing tissue function, and is often accomplished using stem cells. The first type of tissue engineering using stem cells was hematopoietic stem cell transplantation (HSCT), a surgical procedure in which hematopoietic stem cells (HSCs) are infused into a host to treat a variety of blood diseases, cancers, and immunodeficiencies.
Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. (ACT) is a biotechnology company that uses stem cell technology to develop novel therapies in the field of regenerative medicine. Formed in 1994, ACT grew from a small agricultural cloning research facility located in Worcester, Massachusetts, into a multi-locational corporation involved in using both human embryonic stem cells (hESC) and human adult stem cells as well as animal cells for therapeutic innovations.
Subject: Organizations, Reproduction
Ethics and Induced Pluripotent Stem Cells
The recent development of induced pluripotent stem cells (iPSCs) and related technologies has caught the attention of scientists, activists, politicians, and ethicists alike. IPSCs gained immediate international attention for their apparent similarity to embryonic stem cells after their successful creation in 2006 by Shinya Yamanaka and in 2007 by James Thompson and others.
Subject: Technologies, Ethics
"Derivation of Pluripotent Stem Cells from Cultured Human Primordial Germ Cells" (1998), by John Gearhart et al.
In November 1998, two independent reports were published concerning the first isolation of pluripotent human stem cells, one of which was "Derivation of Pluripotent Stem Cells from Cultured Human Primordial Germ Cells." This paper, authored by John D. Gearhart and his research team - Michael J Shamblott, Joyce Axelman, Shunping Wang, Elizabeith M. Bugg, John W. Littlefield, Peter J. Donovan, Paul D. Blumenthal, and George R. Huggins - was published in Proceedings of the National Academy of Science soon after James A.
"Generation of Induced Pluripotent Stem Cells Using Recombinant Proteins" (2009), by Hongyan Zhou et al.
Induced pluripotent stem cells (iPSCs) are studied carefully by scientists not just because they are a potential source of stem cells that circumvents ethical controversy involved with experimentation on human embryos, but also because of their unique potential to advance the field of regenerative medicine. First generated in a lab by Kazutoshi Takahashi and Shinya Yamanaka in 2006, iPSCs have the ability to differentiate into cells of all types.
Nightlight Christian Adoptions, et al. v. Thompson, et al. (2001)
Nightlight Christian Adoptions et al. v. Thompson et al. was a lawsuit filed in the United States District Court for the District of Columbia on 8 March 2001. The suit was filed because Nightlight Christian Adoptions, a frozen embryo adoption agency, felt that the Guidelines for Research Using Human Pluripotent Stem Cells published by the National Institutes for Health were unlawful and violated the restrictions on human embryo research put into place by the Dickey-Wicker Amendment. Additional plaintiffs with this suit were the Christian Medical Association, adult stem cell researcher Dr.
Subject: Legal, Reproduction
"Cell Deaths in Normal Vertebrate Ontogeny" (1951), by Alfred Glücksmann
The review article “Cell Deaths in Normal Vertebrate Ontogeny” (abbreviated as “Cell Deaths”) was published in Biological Reviews of the Cambridge Philosophy Society in 1951. The author, Alfred Glücksmann, was a German developmental biologist then working at the Strangeways Research Laboratory, Cambridge, England. In “Cell Deaths,” Glücksmann summarizes observations about cell death in normal vertebrate development that he had compiled from literature published during the first half of the twentieth century.
Thomson, et al. v. Thompson, et al. (2001)
Thomson, et al. v. Thompson, et al. was a lawsuit filed in the United States District Court for the District of Columbia on 8 May 2001 as Civil Action Number 01-CV-0973. This lawsuit was filed in hopes of gaining injunctive relief against a moratorium on the federal funding of stem cell research. The plaintiffs in the case were seven prominent scientists who performed embryonic stem cell research and three patients: James Thomson, Roger Pedersen, John Gearhart, Douglas Melton, Dan Kaufman, Alan Trounson, Martin Pera, Christopher Reeve, James Cordy, and James Tyree.
"Generation of Germline-Competent Induced Pluripotent Stem Cells" (2007), by Keisuke Okita, Tomoko Ichisaka, and Shinya Yamanaka
In the July 2007 issue of Nature, Keisuke Okita, Tomoko Ichisaka, and Shinya Yamanaka added to the new work on induced pluripotent stem cells (iPSCs) with their "Generation of Germline-Competent Induced Pluripotent Stem Cells" (henceforth abbreviated "Generation"). The authors begin the paper by noting their desire to find a method for inducing somatic cells of patients to return to a pluripotent state, a state from which the cell can differentiate into any type of tissue but cannot form an entire organism.
"Embryonic Stem Cell Lines Derived from Human Blastocytes" (1998), by James Thomson
After becoming chief pathologist at the University of Wisconsin-Madison Wisconsin Regional Primate Center in 1995, James A. Thomson began his pioneering work in deriving embryonic stem cells from isolated embryos. That same year, Thomson published his first paper, "Isolation of a Primate Embryonic Stem Cell Line," in Proceedings of the National Academy of Sciences of the United States of America, detailing the first derivation of primate embryonic stem cells. In the following years, Thomson and his team of scientists - Joseph Itskovitz-Eldor, Sander S. Shapiro, Michelle A.
Subject: Experiments, Publications
"Generation of Induced Pluripotent Stem Cells without Myc from Mouse and Human Fibroblasts" (2007), by Masato Nakagawa et al.
In November 2007, Masato Nakagawa, along with a number of other researchers including Kazutoshi Takahashi, Keisuke Okita, and Shinya Yamanaka, published "Generation of Induced Pluripotent Stem Cells without Myc from Mouse and Human Fibroblasts" (abbreviated "Generation") in Nature. In "Generation," the authors point to dedifferentiation of somatic cells as an avenue for generating pluripotent stem cells useful for treating specific patients and diseases.
Subject: Publications, Experiments
"Alternative Sources of Human Pluripotent Stem Cells" (2005), by Leon Kass and the President’s Council on Bioethics
Human pluripotent stem cells are valued for their potential to form numerous specialized cells and for their longevity. In the US, where a portion of the population is opposed to destruction of human embryos to obtain stem cells, what avenues are open to scientists for obtaining pluripotent cells that do not offend the moral sensibilities of a significant number of citizens?
Subject: Publications, Ethics
President George W. Bush's Announcement on Stem Cells, 9 August 2001
On 9 August 2001, US President George W. Bush gave an eleven-minute speech from his ranch in Crawford, Texas, on the ethics and fate of federal funding for stem cell research. Bush also announced the creation of a special council to oversee stem cell research. In the speech President Bush acknowledged the importance of issues surrounding stem cell research to many Americans, presented different arguments in favor of and opposing embryonic stem cell research, and explained his decision to limit but not completely eliminate potential federal funding for embryonic stem cell (ESC) research.
Shinya Yamanaka (1962- )
Shinya Yamanaka gained international prominence after publishing articles detailing the successful generation of induced pluripotent stem (iPS) cells, first in mice, then in humans. Yamanaka induced somatic cells to act like human embryonic stem cells (hESCs), allowing researchers to experiment with non-embryonic stem cells with a similar capacity as hESCs. The research involving iPS cells therefore offered new potential for research and application in medical treatment, without many of the ethical objections that hESC research entailed.
Barack Obama Executive Order 13505, November 2008
On 20 November 2009 Democrat Barack Obama replaced Republican George W. Bush as president of the United States. Obama soon initiated changes to Bush's 2001 executive order concerning scientific research involving human stem cells. Stem cell research remains a controversial issue in the US. Some individuals consider it immoral to experiment with an embryo because they regard embryos as human beings from the moment of conception, while others believe stem cell research could lead to great scientific advancements.
Michael D. West (1953- )
Michael D. West is a biomedical entrepreneur and investigator whose aim has been to extend human longevity with biomedical interventions. His focus has ranged from the development of telomerase-based therapeutics to the application of human embryonic stem cells in regenerative medicine. Throughout his eventful career, West has pursued novel and sometimes provocative ideas in a fervent, self-publicizing manner. As of 2009, West advocated using human somatic cell nuclear transfer techniques to derive human embryonic stem cells for therapeutic practice.
James Alexander Thomson (1958- )
James Alexander Thomson, affectionately known as Jamie Thomson, is an American developmental biologist whose pioneering work in isolating and culturing non-human primate and human embryonic stem cells has made him one of the most prominent scientists in stem cell research. While growing up in Oak Park, Illinois, Thomson's rocket-scientist uncle inspired him to pursue science as a career. Born on 20 December 1958, Thomson entered the nearby University of Illinois Urbana-Champaign nineteen years later as a National Merit Scholar majoring in biophysics.
George W. Bush Executive Order 13455, June 2007
On 20 January 2001, Republican George W. Bush was sworn in as the forty-third president of the United States, replacing Democrat William J. Clinton. During his eight years in office, Bush issued many executive orders, often altering previous policy. By signing Order 13435 on 22 June 2007, he changed how stem cell research would be performed in America.
Edwin Grant Conklin (1863-1952)
Edwin Grant Conklin was born in Waldo, Ohio, on 24 November 1863 to parents Nancy Maria Hull and Dr. Abram V. Conklin. Conklin's family was very religious and he seriously considered a theistic path before choosing a career in academics. Conklin's scientific work was primarily in the areas of embryology, cytology, and morphology, though many questions regarding the relationships between science, society, and philosophy had an influence on both his writings and academic lectures.
John D. Gearhart
John D. Gearhart is a renowned American developmental geneticist best known for leading the Johns Hopkins University research team that first identified and isolated human pluripotent stem cells from human primordial germ cells, the precursors of fully differentiated germ cells. Born in Western Pennsylvania, Gearhart lived on the family farm located in the Allegheny Mountains for the first six years of his life.